Company profile: Beta Bionics
1.1 - Company Overview
Company description
- Provider of software to reduce the burden of diabetes care, offering the iLet Bionic Pancreas, an insulin delivery system that autonomously manages and administers insulin doses based on continuous glucose monitoring data, with Dexcom G7 CGM integration for real-time dose adjustments and compatibility with prefilled insulin cartridges for convenience and choice among insulin types.
Products and services
- Dexcom G7 CGM Integration: Enables the iLet Bionic Pancreas to integrate with Dexcom G7 for continuous glucose monitoring, facilitating real-time insulin dose adjustments
- ILet Bionic Pancreas: Autonomous insulin delivery system engineered to manage and administer insulin doses using continuous glucose monitoring data for diabetes care
- Prefilled Insulin Cartridge Compatibility: Supports the use of prefilled insulin cartridges, offering users convenience and choice among different insulin types
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Beta Bionics
Embecta
HQ: United States
Website
- Description: Provider of diabetes healthcare products and services, offering insulin syringes in various sizes, including 6mm needles and BD Veo with BD Ultra-Fine markings; BD AutoShield Duo pen needles with dual-end shields; accessories to support injections; and embassador Companion 24/7, a digital platform with educational content, health management tools, and diabetes-friendly recipes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Embecta company profile →
JanOne
HQ: United States
Website
- Description: Provider of pharmaceutical drug candidates targeting severe pain conditions, including JAN101, a twice-daily slow-release oral sodium nitrite formulation for treatment and prevention of peripheral artery disease (PAD) and associated pain, and Jan123, a low-dose naltrexone candidate for complex regional pain syndrome delivered via a unique oral biphasic release tablet.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full JanOne company profile →
Sigrid THx
HQ: Sweden
Website
- Description: Provider of ingested medical devices and platform technologies to lower blood sugar in prediabetics and newly diagnosed type 2 diabetics. Offerings include SiPore21 and the SiPore platform using engineered silica particles acting in the gut without absorption. Conducts clinical trials, including SiPore15 and SiPore21, with potential future indications in obesity, NASH, and infantile colic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sigrid THx company profile →
Glycostasis
HQ: United States
Website
- Description: Provider of engineered human protein technology that releases insulin when blood glucose levels rise and binds it when levels fall, mimicking the natural regulation of insulin in healthy individuals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Glycostasis company profile →
Protomer
HQ: United States
Website
- Description: Provider of pre-clinical biotechnology R&D focused on metabolic diseases, developing glucose-responsive insulin receptor agonist therapeutics and the Molecular Evolution of Peptide Sensors (MEPS) platform for creating therapeutic peptides and proteins with tunable, small-molecule-controlled activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protomer company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Beta Bionics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Beta Bionics
2.2 - Growth funds investing in similar companies to Beta Bionics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Beta Bionics
4.2 - Public trading comparable groups for Beta Bionics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →